Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib + dexamethasone in relapsed/refractory cutaneous T-cell lymphoma (Phase II)
KCT0002953Phase 2Completed
- Sponsor
- Boryung
- Start
- Sep 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib, dexamethasone in cutaneous T-cell lymphoma (CTCL), sponsored by Boryung. Started Sep 2017; status: completed.
02
Drugs
bortezomibdexamethasone
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on KCT0002953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0002953.